Formycon AG / Key word(s): Agreement 25.03.2014 11:44 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- * Leading East European pharmaceutical manufacturer Polpharma joins the first development project as a joint venture partner * Increased marketing potential for Formycon's first biosimilar FYB201 gives reason to expect a greater turnover share for Formycon Munich - Formycon AG announces the involvement of a further partner for the first out-licensed biosimilar development project. Polpharma, a leading East European pharmaceutical manufacturer, is with immediate effect a 50 per cent licence partner in this first Formycon development project alongside Santo Holding GmbH (Andreas and Thomas Strüngmann). Already in December 2013 and ahead of schedule, Formycon was able to successfully out-license the first biosimilar development project to Santo. Polpharma and Santo have now entered into a joint venture for the joint development and marketing of biosimilars. The Formycon biosimilar FYB201 is being integrated into this joint venture. "We welcome the new partner, through whom it will be possible to considerably increase the turnover potential and the market penetration of our biosimilar", says Dr. Nicolas Combé, CFO of Formycon AG. Polpharma, strong in terms of sales and marketing, is a leading manufacturer in Poland with a high profile in other East European countries. Santo Holding is well positioned in Germany, Western Europe and in the South American countries. As a result, the two groups complement each other from both a strategic and geographical point of view. About Formycon AG: Formycon AG is a leading independent developer of biosimilars for global marketing and has taken on a clear pioneering role in this field. The team of the present Formycon AG has amassed many years of experience in the development of complex molecules. As early as 2008 and 2011, two protein-based product portfolios were licensed out to large pharmaceutical companies. As a result of its particular expertise, Formycon AG is in a position to develop high-quality biosimilars that fulfil the strict requirements of the marketing authorisation authorities in the highly regulated countries and regions such as Europe and the USA. Formycon currently has two products under development, with the first biosimilar candidate already having been licensed out to Santo Holding GmbH. Further product developments are in the planning phase. The aim is to be the first company in the world to present clinical data for each respective product candidate and thus to license the products out to large pharmaceutical and generics companies for further development. Alternatively, Formycon offers to bring the biosimilars to marketing authorisation on behalf of the licensee and take over production. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany Tel. +49 (0) 89 - 86 46 67 100 Fax + 49 (0) 89 - 86 46 67 110 [email protected] www.formycon.com Disclaimer: This press release may contain future-oriented statements and information that are recognisable by formulations such as 'expect', 'want', 'anticipate', 'intend', 'plan', 'believe', 'strive', 'estimate', 'will be' or similar terms. Such forward-looking statements are based on our expectations today and on certain assumptions that may entail a range of risks and uncertainties. The results actually achieved by Formycon AG may deviate considerably from the declarations in the future-related statements. Formycon AG will not undertake any commitment to update these future-oriented statements or to correct them in the event that the situation develops differently than expected. 25.03.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Formycon AG Fraunhoferstraße 145 82152 Planegg-Martinsried Germany Phone: 089 864667 100 Fax: 089 864667 110 E-mail: Internet: www.formycon.com ISIN: DE000A1EWVY8 WKN: A1EWVY Listed: Freiverkehr in Berlin; Frankfurt in Open Market (Entry Standard) End of Announcement DGAP News-Service ---------------------------------------------------------------------------